November 2022

Biotech 360°

The AtonRâ Biotech 360 is a long-only, USD-based, actively managed certificate.

The strategy focuses on a newer generation of tools & diagnostics technologies, drugs, and life science services that will revolutionize the future of patient care and not only towards drug developers, which are facing heightened competition, regulatory hurdles, and pricing pressure.

Investments span throughout the entire value chain of drug development in companies with robust and versatile technology platforms that could revolutionize the future of patient care through more efficient and cheaper targeted therapies.  

Main Features
Asset Class Equity
Legal Structure Actively Managed Certificate
Investment Index Long
Launch date 15-Sep-17
Currency USD
Type of Return Total return
Ticker NXSRHEMA
isin XS1365787826
Issuer Natixis
Issue Price 100
Last Price 76.72
Sharpe Ratio -0.23
Correlation 0.87
Beta 1.01
Reference Index ARCA Biotechnology (USD)
Liquidity Daily
# Holdings 27
Management Fees 1.40%
Issuer Fees 0.25%
Performance Fees 15.00%
ALL TIME HIGH ALL TIME LOW
PRICE: 163.8 PRICE: 67.3
DATE: 09-Aug-21 DATE: 11-May-22

Biotech 360°

The AtonRâ Biotech 360 is a long-only, USD-based, actively managed certificate.

The strategy focuses on a newer generation of tools & diagnostics technologies, drugs, and life science services that will revolutionize the future of patient care and not only towards drug developers, which are facing heightened competition, regulatory hurdles, and pricing pressure.

Investments span throughout the entire value chain of drug development in companies with robust and versatile technology platforms that could revolutionize the future of patient care through more efficient and cheaper targeted therapies.  

Monthly Returns $

(Net of fees)

* Estimated
* Actual

JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC ANNUAL
2022 -21.7% -2.9% -0.7% -17.2% -6.3% 5.3% 5.8% -4.0% -10.6% 5.0% 1.5% -40.3%
2021 5.5% -4.7% -7.9% 10.5% -1.6% 9.4% 1.4% -0.2% -3.7% -0.8% -5.4% -6.5% -5.9%
2020 0.0% -3.3% -8.7% 19.2% 7.7% 1.0% 2.2% -2.0% 0.7% -2.9% 14.7% -0.1% 28.6%
2019 12.8% 7.6% -2.2% -4.5% -6.1% 6.1% -4.5% -9.1% -3.4% 0.7% 12.8% 3.9% 11.8%
2018 5.1% -4.9% 0.1% 0.2% 4.2% 2.7% 0.7% 6.9% 2.0% -12.5% 3.5% -9.1% -3.0%
2017 -2.4% 0.5% -1.3% 1.1% -2.1%
Industry Exposure

Top 3 Holdings
  • BIONTECH
  • NEUROCRINE BIOSCIENCES
  • LEGEND BIOTECH
Top 3 Contributors
  • BIONTECH
  • 10X GENOMICS
  • NOVO NORDISK
Worst 3 Contributors
  • CATALENT
  • SCHRODINGER
  • NKARTA
Geographical
Breakdown
Currency
Exposure
Asset
Allocation
Equity Market Cap
Distribution
Equity
Liquidity*

*On average 3 Months daily trading volume

Risk
Scale

5


The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back

Industry Exposure